Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Back In As Of Today
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(147)
•••
Comment by newcoinon Aug 20, 2023 10:20am
192 Views
Post# 35596875

RE:RE:RE:RE:RE:Back In As Of Today

RE:RE:RE:RE:RE:Back In As Of Today

We are now in the middle of the summer doldrums I referred to in this previous post. A share price under three dollars is a gift. I hope everyone is accumulating as I am doing. Shares won't get any cheaper in the next few months.

newcoin wrote: Good to be back, westcoast1000.
My re entry is not without reservation. Let's face it - 25 years now?! Many hearts have been broken.
There does appear to be a preponderance of evidence to suggest this is a fabulous time to own ONC.
Summer doldrums do often set in and if they do again this year it will provide an even better opportunity. I'll have a full position by the end of August.
Very excited to be back!!

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities